Generation of a novel monoclonal antibody that recognizes the alpha (α)-amidated isoform of a valine residue

Benito Antón Palma1*, Philippe Leff Gelman1,2, Mayra Medecigo Ríos1, Juan Carlos Calva Nieves1, Rodolfo Acevedo Ortúño1, Maura Epifanía Matus Ortega1, Jorge Alberto Hernández Calderón1, Ricardo Hernández Miramontes1, Anabel Flores Zamora1 and Alberto Salazar Juárez1

Abstract

Background: Alpha (α)-amidation of peptides is a mechanism required for the conversion of prohormones into functional peptide sequences that display biological activities, receptor recognition and signal transduction on target cells. Alpha (α)-amidation occurs in almost all species and amino acids identified in nature. C-terminal valine amide neuropeptides constitute the smallest group of functional peptide compounds identified in neurosecretory structures in vertebrate and invertebrate species.

Methods: The α-amidated isoform of valine residue (Val-CONH2) was conjugated to KLH-protein carrier and used to immunize mice. Hyperimmune animals displaying high titers of valine amide antisera were used to generate stable hybridoma-secreting mAbs. Three productive hybridoma (P15A4, P17C11, and P18C5) were tested against peptides antigens containing both the C-terminal α-amidated (–CONH2) and free α-carboxylic acid (–COO−) isovariant of the valine residue.

Results: P18C5 mAb displayed the highest specificity and selectivity against C-terminal valine amidated peptide antigens in different immunoassays. P18C5 mAb-immunoreactivity exhibited a wide distribution along the neuroaxis of the rat brain, particularly in brain areas that did not cross-match with the neuronal distribution of known valine amide neuropeptides (α-MSH, adrenorphin, secretin, UCN1-2). These brain regions varied in the relative amount of putative novel valine amide peptide immunoreactive material (nmol/μg protein) estimated through a fmol-sensitive solid-phase radioimmunoassay (RIA) raised for P18C5 mAb.

Conclusions: Our results demonstrate the versatility of a single mAb able to differentiate between two structural subdomains of a single amino acid. This mAb offers a wide spectrum of potential applications in research and medicine, whose uses may extend from a biological reagent (used to detect valine amidated peptide substances in fluids and tissues) to a detoxifying reagent (used to neutralize exogenous toxic amide peptide compounds) or as a specific immunoreagent in immunotherapy settings (used to reduce tumor growth and tumorigenesis) among many others.

Keywords: Valine, Leucine, Antibody, Antisera, Hybridoma, α-amidation, Cross-reactivity, Immunoassay, Immunoconjugate, Neuropeptide

*Correspondence: bapags@gmail.com
1 Molecular Neurobiology and Addictive Neurochemistry Laboratory, National Institute of Psychiatry, Calzada México-Xochimilco #101, 14370 México D.F., Mexico
Full list of author information is available at the end of the article
Background
Over the past few decades, many neuropeptides have been identified in the neural and neuroendocrine structures of both vertebrate and invertebrate species [1, 2]. In vertebrates, more than 50% of the identified neuropeptides and peptide hormones are amidated, whereas more than 90% of bioactive peptides in the brains of invertebrates (i.e., *Drosophila*) are amidated [3]. Most neuropeptides in tissues require post-translational modifications, specifically the α-amidation of the carboxyl group of the C-terminal amino acid. Such amidation represents an essential step for peptide hormones to acquire complete biological activity, receptor recognition, and signal transduction at target cells [4, 5].

C-terminal amidation of peptides, a necessary step for the conversion of prohormones into functional products, is mediated by the activity of the peptidylglycine α-amidating monoxygenase (PAM), a type I membrane protein that is localized to the trans-Golgi network and to secretory granules in neural and endocrine tissues [6]. PAM is a bifunctional enzyme containing two specific domains: (1) peptidylglycine α-hydroxylating monoxygenase (PHM; EC 1.14.17.3) [7, 8] and (2) peptidyl-α-hydroxylycine α-amidating lyase (PAL; EC4.3.2.5) [4, 9].

The cellular bioactivity of PAM depends on ascorbic acid, copper, and molecular oxygen [10, 11]. Mice lacking PAM do not survive beyond mid-gestation [12]. Both of its enzymes act sequentially to generate an active α-amidated peptide product and glyoxylate (Fig. 1a–b) [12].

Although a substantial amount of data is available on the reaction mechanism of PHM [7–11] and its relevance to physiology (i.e., memory and learning retention) [13] and medicine (i.e., intermittent hypoxia associated with sleep apnea) [14], few details concerning the activity and relevance of the PAL domain of PAM have been reported [4]. PHM is a di-copper, ascorbate-dependent monoxygenase that catalyzes the stereospecific α-hydroxylation of a glycine (residue)-extended precursor peptide by molecular oxygen (O₂) [10]; whereas PAL catalyzes the N-dealkylation of the peptidyl-α-hydroxylycine intermediate generated by PHM [10, 11]. In vertebrate species (e.g., human, rat, and *Xenopus*), PHM and PAL are encoded by the same RNA transcript [12, 15], whereas in non-vertebrate species (i.e., *Drosophila*, *Cnidaria*, and *Schistosomes*), each domain appears to be encoded by a separate gene [9].

Although the α-amidation of almost all amino acids found in nature has been observed [1–3, 16], α-amidation of active neuropeptides occurs most frequently on non-polar residues such as phenylalanine (P) (i.e., CCK, FMRF-NH₂) [16], leucine (L) (i.e., amidorphin) [17], methionine (M) (i.e., bombesin) [2], and glycine (G) (i.e., pancreastatin) [18]. In addition, amidation of some residues such as isoleucine (I) (i.e., CRF, urocortin (UCN)3/stresscopin) occurs rarely [19].

Peptides containing the α-amidated isoform of a valine residue represent the smallest group of functional amide neuropeptides displaying pleiotropic bioactivity (i.e., adaptation and survival, energy and metabolic homeostasis, immunomodulation, and stress and anxiety-related responses) that have been identified in neural structures in both vertebrate and non-vertebrate species [1–3, 16–19]. This group of neuropeptides includes distinct bioactive peptide hormones such as, α-MSH [20], metorphamide/adenorphin [21], secretin [22], urocortins (UCN) [23] and enterins [24].

Early research showed that small and large peptide molecules can be separated via reverse-phase liquid chromatography (RP-LC) based on the hydrophobicity of the peptide structure and its amino acid composition [25]. This separation can be followed by sequence analysis of dansylated amino acids via the Edman technique using dansyl chloride as the reagent to label amino acid residues [26]. These studies led to the discovery of two amidated opioid peptides, adrenorphin and amidorphin [17, 21]. With the advent of recombinant DNA technology and cloning procedures [27] together with proteomic analysis using mass spectrometry techniques (LC/MS/MS) [28], the search for mRNA transcripts and mRNA-translated protein products has led to the identification of many functional peptides [28].

In combination with mass spectrometry, monoclonal antibodies (mAbs) became powerful biological tools used in clinical settings [29] and animal studies [30] to detect post-translational modifications of small molecules in tissues [31]. In the present study, we used splenocyte/myeloma cell fusion technology to generate stable hybridomas secreting mAbs against the structural α-amidated isoform of a valine residue with the goal of identifying and characterizing putative novel C-terminal valine amide neuropeptides in the mammalian CNS and neurosecretory tissues, as well.

Immunohistochemical (IHC) analyses showed that valine amidated neuropeptides, such as, α-MSH [32, 33], metorphamide/adrenorphin [34], secretin [35], and UCN [36] are widely distributed throughout the mammalian CNS and neuroendocrine system [37], including the immune system [38]. In general, antibodies generated to characterize the anatomical distribution of valine-amide peptide immunoreactivity in the brain or neuroendocrine tissues required the synthesis of a fragment or peptide motif encoded along the complete amino acid sequence of the peptide of interest, and used then, as the antigenic epitope to which the antibody is targeted [39]. To date, no IHC studies using specific antibodies raised against small isovariants of a single haptenic molecule,
for instance, the free $\alpha$-carboxylic acid or the structural $\alpha$-amidated isoform of an amino acid residue ($\leq$200 kDa) have been studied or reported. Thus, the present paper shows the identification of a single mAb (PC18C5) that displays a high selectivity, sensitivity and specificity for the structural $\alpha$-amidated
isoform of the valine residue when tested against distinct amidated and non-amidated peptide antigens in different immunoassays. Moreover, this mAb exhibited a great capability in detecting endogenous valine amide peptide immunoreactivity along the neuroaxis of the rat brain. Our data demonstrates the high versatility of this mAb, which makes it an amazing biological “tool” for biomedical research and clinical settings.

Materials and methods

Peptide synthesis

Synthetic peptides with the primary sequences [Tyr0]-Gly-Gly-Gly-Val-CONH2 and [Tyr0]-Gly-Gly-Gly-Val-COO− [Tyr-Gly2,4-Val-CONH2] and [Tyr0]-Gly-Gly-Gly-Val-COO− [Tyr-Gly2,4-Val-COO−] were synthesized by Peninsula Labs (USA). Both isovariants of the valine residue, the α-amidated (Val-CONH2) and the free α-carboxylic acid (Val-COO−) isomers, were covalently linked to the C-terminal domain of the peptide backbone and were supplied as lyophilized material at 98 % purity. Both isovariants of the valine residue were used as antigenic epitopes in synthetic peptide constructs and in naturally occurring bioactive peptides to determine the cross-reactivity of the antibodies to each epitope in specific immunoassays. One crucial advantage of using these peptides in immunoassays is that the [Tyr0] residue at the N-terminal domain of these synthetic peptides may be used as a radiolabeled tracer in specific radioimmunoassays (RIAs) when the peptides are labeled as [125I] (see further details below). Moreover, these short oligopeptide constructs, which were synthesized by condensing a triplet of glycine residues [-Gly(3)-] into a peptide backbone, were designed to maintain optimal backbone flexibility, linear conformation, and solubility in aqueous solution, as has been shown for other polymeric structures containing a short linker backbone of glycine residues [40].

Immun conjugates

The structural α-amidated isovariant of the valine residue (Val-CONH2; Sigma–Aldrich, USA) was covalently linked to keyhole limpet hemocyanin (KLH, Sigma) according to standard coupling procedures as previously reported [41], and this complex was used as an immun conjugate for immunization [41]. The free α-carboxylic acid isovariant of valine (Val-COO−) (Sigma–Aldrich, USA) was similarly conjugated to bovine serum albumin (BSA) using 0.2 % glutaraldehyde (Sigma–Aldrich, USA) as a cross-linker [41]. The cross-linking reactions were terminated via the addition of 0.1 M glycine (pH 8) to the reaction mixture. The immun conjugates were dialyzed using a 12 kDa cut-off nitrocellulose membrane (Millipore, USA) for 72 h against 10 L of phosphate-buffered saline (PBS) (pH 7.4) to remove non-reactive aldehydes. Finally, the each immun conjugate was diluted to 1 mg/mL. The purified immun conjugates of BSA-linked peptide(s) were frozen and stored at −20 °C for use as adsorbent antigens in ELISAs and dot-blot assays [41].

Animals

All animal studies and procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23) and were approved by the Animal Care and Bioethics Committee of the National Institute of Psychiatry, Mexico City (NOM -062 -ZOO -1999).

Immunization

Female BALB/c mice (8–9 weeks old, n = 7) were purchased from Charles River Laboratories (Wilmington, MA) and used for immunization and collection of specific antisera according to standard procedures as described previously [39]. The animals, which were designated as R1–R7, received an initial subcutaneous injection of 0.2 mL of a 1:1 emulsion of 50 μg KLH-Val-CONH2 immun conjugate in 0.1 mL of PBS (pH 7.4):0.1 mL of complete Freund’s adjuvant (Sigma–Aldrich, USA). Three subcutaneous booster injections consisting of 0.2 mL of a 1:1 emulsion of 50 μg KLH-Val-CONH2 immun conjugate in 0.1 mL of PBS (pH 7.4):0.1 mL of incomplete Freund’s adjuvant (Sigma–Aldrich, USA) were administered, followed by a final intraperitoneal booster injection of KLH-Val-CONH2 in 0.1 mL of PBS (pH 7.4):0.1 mL of incomplete Freund’s adjuvant 30 days after the previous immunization. Blood (50 μL) was collected from the tail vein of the mice every 2 weeks after each immunization and was centrifuged in an Eppendorf 5804R centrifuge at 1200 rpm for 10 min at 4 °C. The collected sera were stored at −20 °C until further use.

ELISA for polyclonal antibodies

The titers of polyclonal valine amide antisera (VAA) from vaccinated mice were determined via standard antibody-capture ELISA [41] in microtiter 96-well ELISA plates (Immunolon I, Corning). Each well was coated with 0.3 μg of BSA-[Tyr0]-Gly2,4-Val-CONH2 or BSA-RGDV-COO− immun conjugate in the presence of 0.1 M sodium bicarbonate. After overnight incubation, the coated wells were blocked with ELISA buffer [0.5 % teleostean gelatin (Sigma–Aldrich, USA), 0.01 M NaH2PO4 and 0.05 % Tween-20 (Sigma–Aldrich, USA),
pH 7.4) for 2 h at room temperature (RT), washed with ELISA buffer, and incubated overnight at 4 °C in 50 μL of VAA diluted 1:10–1:1000. The wells were subsequently incubated for 2 h at RT in 50 μL of PBS (pH 7.4) containing a 1:5000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G (IgG) (Jackson Immunoresearch, USA) and 0.05 % Tween-20. Color development was performed using the chromogenic reagent O-phenylenediamine dihydrochloride (OPD, Sigma). The plates were measured at 490 nm in an automated ELISA plate reader (EL 311, Bio-Tek Instruments, USA). Preimmune sera from the mice were used as controls. Each assay was performed in triplicate. Vaccinated mice displaying antiserum titers higher than 1:1000 dilution whose sera yielded an A490 reading greater than two standard deviations (SD) beyond the mean of the nonspecific value obtained using preimmune serum were selected as candidates for cell fusion and for the generation of stable productive hybridomas.

**Cell fusion and generation of productive hybridomas**

Hyperimmune mice displaying high antisera titers based on ELISA received an intraperitoneal pre-fusion booster of 50 μg of the KLH-Val-CONH2, immunoconjugate in 200 μL of PBS (pH 7.4) in the absence of adjuvant 7 days before lymphoid cells were harvested [41, 42]. Mice were killed by cervical dislocation; splenocytes were collected before lymphoid cells were harvested [41, 42]. Mice were selected as candidates for cell fusion and for the generation of stable hybridomas due to its high growth rate, rapid replication rate, high capacity for cell fusion, and cloning efficiency [39, 42]. The fused cells were resuspended at a concentration of 2 × 10⁶ cells/mL in a selective enriched hybridoma medium (RPM1640 medium (Gibco, USA) supplemented with 20 % fetal calf serum (FCS)(Gibco, USA), 5 % of a complex mixture of growth factors and cytokines BM Condimed H1 Hybridoma Cloning Supplement (Roche, USA), 50 μg of gentamycin (Sigma–Aldrich, USA), 300 μg/mL L-glutamine (Sigma–Aldrich, USA), 15 mM HEPES (Cellgro), and 5 % hypoxanthine, aminopterin, and thymidine (HAT) (Sigma–Aldrich, USA)]. The fused cells were seeded on a thymocyte feeder layer (3.3 × 10⁵ cells/well) in 20 × 96-well plates (Immunolon I, Corning). Myeloma cells and hybridoma colonies displaying logarithmic growth to a density of 5–6 × 10⁶ cells/mL were diluted to 1 × 10⁵ cells/mL using cryopreservation medium (RPMI1640 medium containing 7 % DMSO and 10 % FCS) and stored at −196 °C under liquid nitrogen in cryogenic vials (Nunc).

**ELISA for mAbs**

ELISAs were used to identify mAbs against Val-CONH₂ secreted by positive colonies using the same protocols as those described for the screening of polyclonal antisera from mice except that BSA-Val-CONH₂, BSA-metorphamide/adrenorphin, BSA-mastoparan-X, BSA-Val-COO⁻, and BSA-RGDV-COO⁻ were used as adsorbent antigens in the wells, that 50 μL of various dilutions (1:50, 1:100, 1:200, 1:400, 1:800, 1:1600, or 1:3200) of the supernatants collected from hybridoma colonies were added to the coated wells, and that the plates were incubated overnight at 4 °C. VAL-CONH₂-ir signal was detected at 490 nm in an automated ELISA plate reader (EL 311, Bio-Tek Instruments, USA) using a 1:5000 dilution of HRP-conjugated goat anti-mouse IgG (Jackson Immunoresearch, USA) and the chromogenic reagent O-phenylenediamine dihydrochloride (OPD, Sigma). The plates were measured at 490 nm in an automated ELISA plate reader (EL 311, Bio-Tek Instruments, USA) using a 1:5000 dilution of HRP-conjugated goat anti-mouse IgG (Jackson Immunoresearch, USA) and the chromogenic reagent OPD (Sigma–Aldrich, USA). VAL-CONH₂ mAb specificity was determined based on the absence of cross-reactivity against the free α-carboxylic acid form of the valine residue (COO⁻) and/or against the C-terminal amide form of the leucine residue (L) in mastoparan X. Preimmune sera from the mice were used as controls in all assays.

**Expansion of hybridomas**

Productive hybridomas secreting antibodies were recovered and subjected to expansion and subcloning procedures at limiting cell dilutions as previously described by Hockfield et al. [41].

**Isotyping**

Isotyping of the mAbs was performed using an IsoQuick Kit for Mouse Monoclonal Isotyping (Sigma–Aldrich, USA).

**Dot–blot assays**

Dot–blot assays were used to assess the mAb specificities against both isovariants of the valine residue in the tested antigens according to standard procedures described by Hockfield et al. [41] and adapted by Loi et al. [43]. Briefly, both isovariants of the valine residue and synthetic BSA-conjugated peptides were tested as potential cross-reactive antigens. Immunconjugates of the BSA-conjugated antigenic peptides Tyr-Gly₂₋₄-Val-CONH₂, Tyr-Gly₂₋₄-Val-COO⁻, RGDV-COO⁻, metorphamide/adrenorphin, and mastoparan X (-Leu-CONH₂) were diluted in 50 % methanol to obtain stock solutions at concentrations of 10⁻²–10⁻⁹ M. Two microliters of each antigenic BSA-peptide immunconjugate at 10⁻¹²–10⁻¹⁶ M were...
spotted onto nitrocellulose membranes (0.45 μm) (Bio-Rad Labs, USA). After spotting the peptides, the dried membranes were soaked in a preblocking solution containing 1% teleostean gelatin (Sigma–Aldrich, USA), 10 mM PBS, and 0.05% Tween-20 (Sigma–Aldrich, USA) (pH 7.4) for 1 h at RT. The membranes were washed 5 times for 5 min with the preblocking solution and incubated overnight at 4°C in the presence of a 1:25 dilution of hybridoma supernatants containing a mAb in 10 mM PBS (pH 7.4). The membranes were then washed and incubated for 2 h at RT in a solution containing 0.05% Tween-20 and 10 mM PBS (pH 7.4) in the presence of HRP-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, USA) diluted 1:20,000. The membranes were washed 5 times for 5 min with 0.05% Tween-20 in 10 mM PBS (pH 7.4) to remove excess secondary antibody. Signal detection was performed using a chemiluminescence kit (NEN, Cat. No. NEL-101; Life Sciences, USA).

**Solid-phase RIA**

A solid-phase RIA for the α-amidated isovariant of the valine residue was adapted from standard procedures described by Hockfield et al. [41]. Briefly, the N-terminal [Tyr0] residue of the synthetic peptide Tyr-Gly2-4-Val-CONH2 was iodinated with [125I] using the IODO-GEN protein labeling procedure (Pierce, USA) according to the manufacturer’s protocol, and the peptide was purified via high-performance liquid chromatography using Hypersil wide-pore 5-μm, C-8, 2 × 150 mm columns. The solid-phase RIA was prepared by loading 100 μL of blocking solution containing 500 ng protein A (Sigma–Aldrich, USA) and 0.1 M NaHCO3 (pH 9) in Immunolon II removable wells (VWR), followed by incubation overnight at 4°C. The coated wells were washed 3 times for 10 min with RIA buffer [0.15 M K2HPO4, 0.2 % Tween 20 (Sigma–Aldrich, USA), and 0.1 % teleostean gelatin (Sigma–Aldrich, USA), pH 7.4]. Fifty microliters of RIA buffer containing a hybridoma supernatant at 1:20 dilution were added to the wells in quadruplicate, and the plates were incubated overnight at 4°C (this dilution was previously shown to result in approximately 20–30% binding). After removing the antibody solution and washing with RIA buffer, 50 μL of RIA buffer containing competitive peptides (0.1 fmol–10 nmol/well in quadruplicate) and the radiolabeled peptide tracer were applied to the adsorbed anti-Val-CONH2 mAbs for 2 h at RT. Typical standard displacement curves were generated using approximately 5000 c.p.m. of the radiolabeled tracer [125I]-Tyr-Gly2-4-Val-CONH2 and the non-labeled peptides used in the competitive RIA [Tyr-Gly2-4-Val-CONH2, BSA-Val-CONH2, BSA-Val-COO−, RGDV, metorphamide/adrenorphin, and mastoparan X]. The treated wells were washed and counted for 4 min in a 10-channel gamma counter (ISODATA 500, Hewlett-Packard).

**Peptide fractions from neural and endocrine tissues**

Tissue extraction and preparation of whole peptide fractions from various neural and endocrine tissues were performed according to standard procedures and the protocols previously described by Asai et al. [44]. Briefly, male Wistar rats (250–300 g, n = 20) pre-anesthetized with lethal doses of sodium pentobarbital (50 mg/kg, i.p.) were decapitated, and the abdominal cavity was opened for surgical extraction of the pancreas and the adrenal glands. Rat brain regions such as the cortex, the hippocampus, the striatum, the hypothalamus, the thalamus, the cerebellum (Cb), the pituitary and the spinal cord and endocrine glands including the adrenal gland and the pancreas were rapidly dissected on ice. The brain regions and the glands were promptly homogenized using a tissue homogenizer (Polytron PT10/35) at 800 rpm in an ice-cold acid/acetone solution (12 N HCl:H2O:acetone, 16:6:40, v:v) and centrifuged at 12,000 × g for 1 h at 4°C in a Sorvall RC28S centrifuge (DuPont, USA). The HCl:acetone solution was removed from the crude peptide fraction supernatants via vacuum evaporation (Eppendorf Centrifuge Concentrator 5301, Germany). The dried pellets were resuspended in 5% TFA solution and loaded on Sep-Pak-RP C-18 columns (Waters Inc., USA) pre-activated with 100% TFA for solid-phase peptide extraction. The peptide fractions from tissue homogenates of the brain and the endocrine glands were eluted from the columns using 20% TFA:H2O2, dried via vacuum evaporation and stored at −20°C. The thawed pellets were resuspended in a solution containing 50 mM Tris–HCl, pH 8.4, and 2.0 mM CaCl2, and 50-μL aliquots of RIA buffer containing a 1:5–1:500 dilution of a purified peptide fraction were individually assessed for the P18C5 mAb via solid-phase RIA using the radioactively labeled peptide [125I]-Tyr-Gly2-4-Val-CONH2. The labeled tracer was used to quantify the abundance of Val-CONH2-ir in the tissues. Peptide immunoreactivity in the samples is expressed as nmol/μg protein (mean ± standard error of the mean, SEM).

**Protein concentration determination**

The protein concentrations in the peptide fractions extracted from the rat brain and neuroendocrine tissues were determined according to standard procedures using the Micro-BCA Protein Assay Kit (Pierce, Rockford, IL, USA; Cat No. 23235) based on the instructions provided by the manufacturer. The absorbance at 570 nm was measured using a microwell plate reader (EL 311, Bio-Tek).
IHC analysis of Val-CONH₂-ir in brain and neuroendocrine tissues.

1 month in the aforementioned solution does not result in float freely in 10 mM PBS (pH 7.4)/0.05 % sodium azide collected in 12-well plates (Corning, USA), allowed to m-thick coronal sections. The sliced sections were 40-μm-thick sagittal sections using a cryostat (Reichert-Jung 3050); alternatively, the fixed neuroendocrine tissues were sliced into 40-μm-thick coronal sections. The sliced sections were collected in 12-well plates (Corning, USA), allowed to float freely in 10 mM PBS (pH 7.4)/0.05 % sodium azide solution, and stored at 4 °C until use. Storage for up to 1 month in the aforementioned solution does not result in loss of immunoreactivity [45].

Tissue preparation

Tissue preparation for IHC detection of Val-CONH₂-ir was performed according to standard procedures previously described by Anton et al. [45]. Briefly, six male Wistar rats (250–300 g) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) (Anesket, PISA Lab, Mexico) and transcardially perfused with 250 mL of 10 mM PBS (pH 7.4)/heparin (5 U/mL) solution, followed by perfusion with 800 mL of 4 % paraformaldehyde/10 mM PBS (pH 7.4) solution at 4 °C. The flow rate was held constant (10 mL/min) using a Hamilton double-pumping system (Hamilton, USA). Fixed tissues from the brain, hypophysis and adrenal glands were cryoprotected in 30 % sucrose/10 mM PBS (pH 7.4) solution for 3 days at 4 °C. The fixed brain tissues were sliced into 40-μm-thick sagittal sections using a cryostat (Reichert-Jung 3050); alternatively, the fixed neuroendocrine tissues were sliced into 40-μm-thick coronal sections. The sliced sections were collected in 12-well plates (Corning, USA), allowed to float freely in 10 mM PBS (pH 7.4)/0.05 % sodium azide solution, and stored at 4 °C until use. Storage for up to 1 month in the aforementioned solution does not result in loss of immunoreactivity [45].

Immunohistochemistry

IHC analysis of Val-CONH₂-ir in brain and neuroendocrine tissue slices was performed according to standard procedures described previously [45] with minor modifications. Briefly, both brain and neuroendocrine tissue sections were processed while free-floating and were initially washed in 10 mM PBS (3 times for 10 min each) followed by 10 % NaBH₄ in 10 mM PBS for 15 min. After three additional 10-min washes in 10 mM PBS, the tissue sections were permeabilized with 0.3 % Tween-20 in 10 mM PBS for 20 min and washed with 10 mM PBS (three times for 10 min each). Then, endogenous peroxidase activity was blocked for 40 min in a 0.3 % hydrogen peroxidase/0.1 % Tween-20/10 mM PBS (pH 7.4) solution. Following three additional 10-min washes in 10 mM PBS, the sections were incubated for 4 h in a preblocking solution containing dialyzed 10 % horse serum, 1 % BSA, 0.3 % Tween-20, and 10 mM PBS (pH 7.4). The sections were then incubated on an orbital shaker for 16 h at 4 °C in the primary valine amide MAb PC18C5 diluted 1:40 in the preblocking solution [10 % dialyzed horse serum, 0.3 % Tween-20, and 10 mM PBS (pH 7.4)]. After 5 10-min washes with 10 mM PBS, the sections were incubated for 2 h in a donkey anti-mouse biotinylated (IgG) secondary antibody (Jackson ImmunoResearch, USA) diluted 1:2000 in pre-blocking solution [5 % dialyzed horse serum, 1 % BSA, 0.3 % Tween-20, and 10 mM PBS (pH 7.4)]. After 1 and 5 10-min washes with the preblocking solution and with 0.3 % Tween-20/10 mM PBS (pH 7.4) solution, respectively, the sections were incubated in the avidin–biotin complex (ABC Elite Vector Kit; Vector, Burlingame, CA), followed by 310-min washes with 0.1 % Tween-20 in 10 mM PBS and by 3 10-min washes with 10 mM PBS (pH 7.4). Color development was enhanced by a 5–10 min incubation in a 0.06 % 3,3′-diaminobenzidine tetrahydrochloride (DAB, Sigma)/0.03 % H₂O₂/0.3 % nickel sulfate/10 mM PBS (pH 7.4) solution. The sections were then washed in 10 mM PBS, mounted on slides, and air-dried overnight. The prepared slices were cleaned with xylene and cover-slipped with Entellan (Merck). Microscopic analysis of the brain sections was performed under bright-field illumination using a DAS LEICA DMR Qwin microscope. Positive immunoreactivity detected by the PC18C5 mAb in tissue slices is referred as valine amide-like immunoreactivity (VAL-CONH2-ir). The neuroanatomical areas displaying positive VAL-CONH2-ir signal were identified according to the atlas of the rat brain by Paxinos and Watson (1998) [46].

Controls

As a control of labeling specificity, adjacent slices from rat neuroendocrine tissues and brain sections were pre-absorbed with 10 μM of the valine amide residue (Val-CONH₂) (Peninsula Labs, USA). The intensity and the density of positive PC18C5 mAb-immunoreactive signal in the brain were compared to those of Val-CONH₂-ir detected in the pituitary and adrenal glands as shown in Fig. 2a–c. Both tissues were as used internal standards, and the immunoreactive signals were arbitrarily graded using a similar grading scale to the scale used to map the distribution of ORL-1 receptor immunoreactivity in the rat brain [45] as follows: very intense (++++); intense (+++); moderate (++); low (+); and not detected (0).

Subtraction analysis

Immunoreactive signals produced from peptide antibodies used to map the anatomical distribution of C-terminal valine amide neuropeptides [i.e., metorphamide, secretin, α-MSH, and UCNs] in the rat CNS and neuroendocrine tissues were used as a reference to subtract from PC18C5 mAb-ir signals detected in the rat CNS. Positive PC18C5 mAb-ir signals in brain areas that did not match with previously identified C-terminal amide–peptide immunoreactivity, were considered as potential brain areas expressing putative novel valine amide neuropeptides. Positive Val-CONH2-ir signals detected in subtracted brain regions were arbitrarily graded as follows: very intense (4); intense (3); moderate (2); low (1); or not detected (0) (see Fig. 3).
Results

Identification of hyperimmune vaccinated mice

Immunization of female BALB/c mice (8–9 weeks, n = 7) with the KLH-Val-CONH₂ immunoconjugate after five consecutive booster injections produced animals exhibiting antibody responses against the α-amidated isoform of the valine residue (Val-CONH₂) (Fig. 4). VAAs collected from five (R1, R2, R4, R6, and R7) of the seven vaccinated mice displayed significantly high cross-reactive signal against the BSA-Tyr-Gly₂-⁴-Val-CONH₂ adsorbed antigen based on ELISA; these signals were twofold higher than the non-specific A₄₉₀ values detected for the pre-immune control serum at the tested dilutions (1:100–1:1000). However, the VAAs from the vaccinated animals did not display significantly higher cross-reactive signal than the controls for the free α-carboxylic acid isoform of the valine residue in the BSA-RGDV-COO⁻ antigen (data not shown). The criteria for the selection of the samples for the cell fusion procedures were based on the detection of high immunoreactive signals (A₄₉₀ values) against the α-amidated isoform of the valine residue in the BSA-Tyr-Gly₂-⁴-Val-CONH₂ immunoconjugate at the highest antisera dilution tested (1:1000) in vaccinated animals and on the lack of immunoreactivity for the carboxylic acid form of the same residue in the BSA-RGDV-COO⁻ antigen (see the “Materials and methods” section). Among the five hyperimmune animals (R1, R2, R4, R5, and R7) selected for the generation of hybridoma-secreting mAbs, mouse R4 exhibited the highest cross-reactivity against BSA-Tyr-Gly₂-⁴-Val-CONH₂, displaying high titers of antibodies at VAA dilutions of 1:100 (A₄₉₀ = 0.062 ± 0.002, mean ± SEM) and 1:1000 (A₄₉₀ = 0.0034 ± 0.0002; mean ± SEM) (Fig. 4).

Productive hybridomas

Cell fusion of activated splenocytes from mouse R4 with the murine myeloma Sp2/0 cells yielded 340 stable hybridomas (17.8 %) from a total of 1920 seeded cells (data not shown). ELISA revealed three stable hybridoma-forming colonies (0.0015 %), designated as P15A4, P17C11, and P18C5; these three colonies secreted mAbs that recognized the cognate epitope of Val-CONH₂ in both the BSA-Val-CONH₂ and BSA-Tyr-Gly₂-⁴-Val-CONH₂ immunoconjugates (data not shown). The hybridomas secreting mAbs displayed cross-reactivity against the α-amidated isoform of the valine residue represented 8.8 % of the total productive hybridomas formed after cell fusion. Isotyping of the immunoglobulin class of the mAbs secreted by these three hybridomas showed that they belonged to the IgG1 class.

ELISA

ELISAs were evaluated as an initial step in characterizing the specificity of the three distinct antibodies (P15A4,
against the structural α-amidated form of the valine residue. Immunoconjugates of amidated and non-amidated Val- and Leu-containing peptides linked to BSA were used as adsorbed antigens in the assays (see the Materials and methods section). The P15A4 and P17C11 mAbs displayed no differences in cross-reactivity against the adsorbed antigens of BSA-Val-CONH₂, BSA-Tyr-Gly₂-₄-Val-CONH₂, metorphamide (YGGFMRRV-CONH₂), BSA-Val-COO⁻, or mastoparan X (INWKGIAMAKKLL-CONH₂) at the tested antibody dilutions (1:50–1:6400) (data not shown).

However, the P18C5 mAb displayed a distinct pattern of reactivity against the α-amidated and free carboxylic acid isovariants of the valine residue in the tested antigens, as depicted in Fig. 5. As shown, the P18C5 mAb exhibited high evident cross-reactivity against the α-amidated form of the valine residue in BSA-Val-CONH₂, at both low and high antibody dilutions (1:50–1:6400). Notably, a less apparent immunoreactive response was detected against the metorphamide/adrenorphin peptide antigen. Cross-reactivity with the latter antigen decayed rapidly at the initial working dilutions of the antibody (1:50–1:200), in contrast to the slow decay of immunoreactive signal for the BSA-Val-CONH₂ antigen at higher dilutions (1:800). However, the P18C5 mAb cross-reacted with the antigenic isovariants of the valine residue in the BSA-Val-COO⁻, BSA-Tyr-Gly₂-₄-Val-CONH₂, BSA-Tyr-Gly₂-₄-Val-COO⁻, and BSA-RGDV-COO⁻ immunoconjugates, including the α-amidated isoform of Leu in the mastoparan X peptide antigen. The immunoreactive signals against these antigens were 4.5- and 21.4-fold lower than those against the
against the metorphamide and YGGG-Val-CONH₂ peptide antigens at the highest peptide concentration tested (10⁻¹² M), showing moderate immunoreactive signals against the peptide at lower peptide concentrations (10⁻¹³–10⁻十四 M). However, a weak immunoreactive signal was observed against Mastoparan X at the highest concentration tested (10⁻¹² M), and no signals were observed at lower concentrations (10⁻¹³–10⁻十四 M). Interestingly, no immunoreactive signals against both YGGG-Val-COO⁻ and RGDV-COO⁻ antigens were detected at any of the peptide concentration tested. Thus, the P18C5 mAb showed superior antibody selectivity against the α-amidated form of the valine residue.

Based on the high specificity and selectivity of the P18C5 mAb for the α-amidated form of the valine residue in peptide antigens based on ELISAs and dot–blot assays, a sensitive solid-phase RIA for P18C5 mAb was developed and used to further assess the specificity and selectivity of this hybridoma-secreted mAb. Validation of the sensitivity of this RIA enabled further identification and characterization of putative novel valine–amide neuropeptides from brain and neurosecretory tissues of rodents in subsequent studies.

**Solid-phase RIA**

A fmol-sensitive solid-phase RIA for the P18C5 mAb was developed using both the structural α-amidated isoform and the free carboxylic acid form of the valine residue conjugated to BSA, including both the C-terminal amidated peptides and synthetic non-amidated peptides, using the synthetic [¹²⁵I]-Tyr-Gly₂₋₄-Val-CONH₂ as the labeled tracer (see the Materials and methods section). A representative RIA showing typical displacement curves by synthetic [¹²⁵I]-Tyr-Gly₂₋₄-Val-CONH₂ using the P18C5 mAb is depicted in Fig. 6. As shown, the P18C5 mAb recognized non-labeled Tyr-Gly₂₋₄-Val-CONH₂ over the tested concentration range, with an IC₅₀ of 154.4 ± 48.3 fmol/well; the smallest measured displacement value, detected at IC₅₀ was 64.8 ± 11.6 fmol/well, and the highest was 710.2 ± 89.8 fmol/well at IC₂₀ based on this assay. In the same context, metorphamide was bound at an IC₅₀ of 64.6 ± 9.7 fmol/well, and its lowest and highest displacement values were detected at the IC₈₀ (26.9 ± 7.3 fmol/well) and the IC₂₀ (179.7 ± 44.8 fmol/well), respectively. Similar displacement values were observed for BSA-VAL-CONH₂. The P18C5 mAb detected BSA-VAL-CONH₂ at an IC₅₀ of 111.97 ± 32.4 fmol/well, an IC₈₀ of 53.7 ± 12.7 fmol/well, and an IC₂₀ of 458.56 ± 69.9 fmol/well. Moreover, no significant cross-reactivity against mastoparan X was observed for the concentration range of competitive peptides (0.1 fmol–10 nmol) tested in this assay. Furthermore, the P18C5 mAb failed to recognize the structural free carboxylic acid isoform of the valine residue.
residue in both Tyr-Gly2-4-Val-COO⁻ over the tested concentration range of the competitive peptide antigens (IC₅₀, non-determined), except for the lowest measurable displacement values detected at the IC₈₀ for Val-COO⁻ peptides (>2152.1 ± 469.6 fmol/well) and for mastoparan X (>8125.2 ± 1675.8 fmol/well).

P18C5 mAb immunoreactivity in control tissues
Isotyping analysis of the P18C5 mAb showed that it is classified as an IgG1 antibody. As shown in Fig. 2a–c, P18C5 mAb immunostaining was abolished in control tissues of the hypophysis, the adrenal gland, and representative sagittal sections of the rat brain when the antibody was pre-absorbed with 10 μM of the synthetic Val-CONH₂ compound. The intermediate lobe of the hypophysis (IL) displayed intense P18C5 mAb immunolabeling (Fig. 2a, left panel). Pre-absorption with the synthetic amidated valine compound completely abolished P18C5 mAb staining in this region (Fig. 2a, right panel). Furthermore, the chromaffin cell-rich area of the adrenal gland [the adrenal medulla (me)] displayed intense P18C5 mAb immunolabeling (Fig. 2b, left panel). Pre-absorption with the synthetic amidated valine compound completely blocked immunostaining in the core area of the adrenal gland (me) in adjacent tissue sections using the P18C5 mAb (Fig. 2b, right panel). In control sections of the rat brain (Fig. 2c), the P18C5 mAb produced intense immunolabeling in several areas (Fig. 2c, upper panel). Pre-absorption with the synthetic valine amide resulted in complete abolishment of P18C5 mAb...
immunostaining in adjacent brain sections (Fig. 2c, lower panel).

**P18C5 mAb immunoreactivity in the rat CNS**

Val-CONH$_2$-ir was distributed widely throughout the neuroaxis of the rat brain after immunostaining using the P18C5 mAb (see the Materials and methods section) (Fig. 7a–e). Moderate to intense immunolabeling was predominantly localized to the neuropil, displaying scattered stained neuron-like cell bodies appearing in several regions within the rat brain. A brief summary of the distribution of P18C5 mAb immunoreactivity in the rostrocaudal areas of the rat CNS is described below.

**Telencephalon**

Several telencephalic regions exhibited moderate to high immunolabeling, which was predominantly distributed in thin and dense fiber processes, oval-to-round somata, and diffuse fine puncta (Fig. 7a–e). PC18C5 mAb immunoreactivity (P18C5 mAb-ir) was detected in the primary and secondary motor cortices (M1 and M2, respectively), parietal sensorimotor cortical fields, and the primary and secondary visual cortices (V1M and V2MM, respectively) (Fig. 7a–e), as well as the retrosplenial agranular (RSA) and granular A (RSGa) cortices (Fig. 7b). Within the olfactory system, P18C5 mAb-ir was observed in both the main olfactory bulb (OB) and the accessory olfactory bulbs (Fig. 7c–e). In the hippocampus (Hi), P18C5 mAb-ir was found in the striatum pyramidale and radiatum, along the CA1–CA3 fields of Ammon’s horn, and, particularly, in the granular cell layer of the dentate gyrus (DG), as well as in the fimbria (fi) and the subiculum (S) (Fig. 7a–e). P18C5 mAb-ir was also detected in the basal ganglia [i.e., the caudoputamen (CPu), the core (AcbC) and shell (AcbSh) areas of the nucleus accumbens (NACC), and the ventral pallidum (VP)], sepal areas [i.e., the stria terminalis (BST), the lateral (BSTL) and medial BST (BSTM), the bed nucleus of the anterior commissure (BAC), the lateral septum (LS), the dorsal part of the LS (LSD), the substantia innominata (SI), and the nucleus of the horizontal limb of the diagonal band (HDB)] and the amygdala [anterior
(Aco), including the posterolateral (PLCo), and posteromedial cortical amygdaloid nuclei (PMCo), which displayed moderate to high immunostaining that was predominantly distributed in sparse neuropil, stained round-to-oval cell bodies, and fine dendritic puncta (Fig. 7a–e). Both the medial amygdaloid nucleus (Me) and the amygdalo-hippocampal area (Ahi) exhibited low levels of mAb-ir (Fig. 7a).
Diencephalon
P18C5 mAb-ir was observed in several diencephalic structures, including the hypothalamus [i.e., the anterior hypothalamic (AH) and lateral hypothalamic areas (LH) and the supraoptic (SO) and arcuate nuclei (Arc)], which displayed moderate to intense mAb immunostaining, (Fig. 7d–e). Both the thalamus (Th) i.e., the anteroven¬tral (AVVL), lateral posterior (LPMR) and mediodorsal nuclei (MD)] and the subthalamic nuclei (STh) (Fig. 7a–c), including several mammillary nuclei i.e., the medial mammillary (MM), lateral mammillary (ML), and sub¬mammilothalamic nuclei (SThM)], displayed low to moderate mAb immunolabeling (Fig. 7a–e). The stained regions included the retrochiasmatic supraoptic (SOR) nucleus of the hypothalamus (Fig. 7a–c).

Mesencephalon
Along the mesencephalon, P18C5 mAb-ir was detected in the substantia nigra (SN, pars compacta, pars reticular¬aris, and pars lateralis) (Fig. 7a–c), the superior colliculus (SC) [i.e., the zonal layer (Zo)], the inferior colliculus (IC) (i.e., the central nucleus) (Fig. 7c–e), the ventral tegmental area (VTA), the red nucleus (R) and the lateral periaqueductal gray area (LPAG) (Fig. 7e). These mesencephalic areas generally displayed low to moderate mAb immunolabeling that was predominantly localized within a network of fiber processes dispersed among stained somata (Fig. 7a–e).

Cerebellum
PC18C5 mAb-ir was predominantly distributed along the Purkinje cell layer of the cerebellar cortical layers; cells in this area displayed highly stained somata-like cell bodies, fine dendritic puncta, and a very dense network of pro¬truding labeled Purkinje cell axon fibers (Fig. 7a–e). Low to moderate mAb-ir was detected in both the flocculus (fl) and the white matter of the Cb, including the medial cerebellar peduncle (mcp) (data not shown).

Pons and medulla
The PC18C5 mAb showed low to moderate immuno¬staining in nuclei and tracts along the rostrocaudal aspects of the pontine and medullary areas of the rat CNS (Fig. 7a–e). Within the most lateral aspects of the pontine/medullary areas of the brain, low to moderate mAb-ir was detected at the retronuclear nucleus (RR), the ventral nucleus of the lateral lemniscus (VLL), the lateral nucleus of the superior olive (LSO), the cuneate nucleus (Cu), and the lateral vestibular nucleus (LVE) (Fig. 7a). In addition, the pontine nucleus (Pn), both the medial (MPB) and lateral parabrachial nuclei (LPB), both the anterior (IntA) and posterior parts of the interposed cerebellar nuclei (IntP), and the spinal vestibular nucleus (SpVe) showed positive immunostaining (Fig. 7b–c). Within the medial aspects of these caudal regions of the rat brain, positive mAb-ir was detected at the locus coere¬neus (LC), the parvocellular (MvePC) and magnocellular parts of the medial vestibular nuclei (MveMC), and both the laterodorsal tegmental nucleus (LDTg) and the dorsal part of the inferior olive (IOD), including the central gray matter of the pons (CGPn) and the solitary tract (Sol) (Fig. 7d–e).

Valine amide peptide immunoreactivity in the rat brain
The reports describing the immunoreactive distribu¬tion of α-MSH, metorphamide, secretin and UCN1-2 in the rat brain [32–36] were used to compare each peptide immunoreactivity with the rostrocaudal distribution of P18C5 mAb-ir in the rat CNS, as depicted in Fig. 7a–e, respectively.

Subtraction analysis
P18C5-mAb-ir detected along the rostrocaudal areas of the rat brain (Fig. 7a–e) was compared with the distribu¬tion of valine amide peptide immunoreactivities detected in the rat brain. The immunoreactive signals obtained for each peptide were subtracted from PC18C5 mAb-ir signals detected along the neuroaxis of the rat brain. The subtracted brain areas expressing Val-CONH2-ir material are depicted in Fig. 3. Most of these areas showed moderate-to-high PC18C5 mAb-ir signals, with the exception of the cerebellar lobes (i.e., the anterior, posterior and flocculonodular lobes) and the lateral hypothalamus (LH) which exhibited an intense P18C5-mAb-ir signals, similar to immunoreactive signal displayed by the IL of the hypophysis, used as the internal control tissue.

As shown in Fig. 3, valine amide peptide immunoreac¬tivity (VAP-ir) was detected in cortical areas of the tel¬encephalon such as M2, the hindlimb (S1HL) and trunk regions of the primary somatosensory cortex (S1Tr), the parietal association cortex (PtA), V2MM, and V2ML. In addition, CVAP-ir was observed in the main accessory OB (AOB) and corresponding nuclei, described as the anterior accessory olfactory nucleus dorsal (AOD), the nucleus ventral (AOV), the nucleus lateral (AOL) and the nucleus medialis (AOM). Furthermore, VAP-ir was detected along the olfactory tubercle (Tu), within the bed nucleus of the accessory olfactory tract (BAOT) and within the nucleus of the lateral olfactory tract (LOT). In addition, CVAP-ir was detected in telencephalic structures such as S of the Hi, NACC, and the substan¬tia innominata of the LS, including both the Ahi and the amygdalo-anterior area (AA) of the limbic system. In the diencephalon, VAP-ir was found in LPMR of the thala¬mus and in the magnocellular portion of the LH. Within the mesencephalon, VAP-ir was primarily localized to
the lateral portion of the substantia nigra (SNL) and Zo of the SC, whereas in the pontine and medullary areas, CVAP-ir was primarily localized to RR, Sol and the fl of the Cb.

**Peptide fractions displaying VAP-ir**

Several regions of the rat brain and endocrine glands were used to prepare purified peptide fractions from the subtracted brain areas to quantify the content of VAP-ir (expressed as nmol/μg protein) using the specific solid-phase RIA generated for the P18C5 mAb (Fig. 6). In addition, neuroendocrine glands (pituitary, adrenal and pancreas) were used as control tissues in the assay. As shown in Fig. 8, the rat pituitary (PIT) displayed the highest abundance of VAP-ir (2.34 ± 0.4672 nmol/μg protein; mean ± SEM), which was 2.1-fold greater than the amount observed in the brainstem (1.09 ± 0.21 nmol/μg protein; mean ± SEM). However, low amounts of Val-CONH2-ir were detected in the cortex (0.41 ± 0.06 nmol/μg protein; mean ± SEM) and in the adrenal glands (AD) (0.35 ± 0.052 nmol/μg protein; mean ± SEM); these levels were 6.7- and 14.6-fold lower, respectively, than the levels measured in the pituitary. In the same context, both the Cb (0.026 ± 0.004 nmol/μg protein; mean ± SEM) and the pancreas (0.042 ± 0.005 nmol/μg protein; mean ± SEM) contained low levels of Val-CONH2-ir, specifically 90- and 56-fold lower, respectively, than those in the pituitary.

![Fig. 8](image.png)

**Fig. 8** Quantification of endogenous valine amide peptide-immunoreactive material in tissues. The abundance of valine amide peptide-immunoreactive material was estimated in purified peptide fractions prepared from subtracted brain regions (CB, CX, BS) and neuroendocrine glands (PIT, PNCR), which displayed moderate-to-high PC18C5 mAb immunolabelling (see Figs. 2 and 7) based on the solid-phase RIA developed for the PC18C5 mAb (inset). The plot shows that the highest abundance of Val-CONH2-ir material was found in the pituitary (PIT) (2.34 ± 0.4672 nmol/μg protein; mean ± SEM), followed by the brainstem (BS) (1.09 ± 0.021 nmol/μg protein; mean ± SEM), the adrenal gland (AD) (0.35 ± 0.052 nmol/μg protein; mean ± SEM), and the cortex (Cx) (0.41 ± 0.06 nmol/μg protein; mean ± SEM). Inset depicts a representative solid-phase RIA for the PC18C5 mAb used for the quantification of valine amide-immunoreactive material in the assays. Tyr-Gly(3)-Val-CONH2 was used as a standard to construct a typical standard curve and was detected at a concentration of 154.2 fmol/well at the IC50 value, whereas metorphamide/adrenorphin (used as a competitive peptide antigen) was detected at a concentration as low as 7.9 fmol/well at the IC50 value (see text for additional details).
Discussion

The α-amidation process is an essential step for the conversion of prohormones into mature peptides that possess complete biological activity, which includes receptor recognition and transduction of peptide hormone signals in target cells [4, 5, 10]. The α-amidation process has been shown to occur most frequently on neutral amino acids (L, F, G) in neuropeptides, which constitute the largest group (>50%) of functional peptide messengers identified in vertebrate and/or invertebrate species. Such peptides display pleiotropic activities across species [2, 3, 16]. However, valine amide peptide hormones represent the smallest group of functional amidated peptides identified to date, and which include the enterochromaffin cell-related peptide hormone, secretin, which belongs to the PACAP/VIP/glucagon peptide hormone family [22, 50]; the POMC-derived peptide-α-MSH [47]; the proenkephalin A-derived metorphamide/adrenorphin [48]; the stress and appetite regulatory urocortins (UCN1-2) [23, 49] and the enterins, a family of brain peptides found in the enteric nervous system of Aplysia, which modulate both feeding non-feeding behaviors in this marine specie [24].

In order to search for neural structures expressing putative novel valine amide peptide immunoreactive material in the brain and neurosecretory tissues of mammals, we employed splenocyte/myeloma cell fusion procedures, with the aim to generate stable hybridoma-producing mAbs able of recognizing the structural α-amidated isoform of the valine residue (Val-CONH₂) in constructed immun conjugates (see material and methods and Figs. 5 and 6).

Cell fusion procedures between activated splenocytes from the hyperimmune female BALB/c mouse-R4—(Fig. 4) and the murine myeloma cell line Sp2/0, led to the identification of three hybridoma-producing mAbs (out of 340 screened hybridoma-forming colonies) designated as P15A4, P17C11, and P18C5 and which displayed different levels of cross-reactivities against the structural α-amidated and/or the free carboxylic acid iso variants of the valine residue expressed in distinct antigens tested in different immunoassays (ELISA, dot–blots and solid-phase RIA) used to validate the specificity and selectivity of these mAbs (see Figs. 5 and 6). The efficiency of the cell fusion procedure from the total cells seeded for fusion was 0.016%, a value considered within the efficient rates reported in the generation of productive hybridomas [41, 42].

As shown, only P18C5 mAb showed a predominant cross-reactivity against the α-amidated isoform of the valine residue in the tested antigens in ELISA and dot-blot assays (Fig. 5). However, P18C5 mAb showed to be exquisitely selective for the structural α-amidated isoform of the valine residue in the constructed synthetic antigens (Methorphamide, BSA-Val-CONH₂, Tyr-Gly₂-₄-Val-CONH₂) tested in the fmol-sensitive solid phase RIA (Fig. 6) but unable to recognize the free carboxylic acid of same residue in both RDGV, Tyr-Gly₂-₄-Val-COO⁻ peptide antigens (within the range of IC₅₀ values detected for the valine amidated antigens, including Mastoparan X [a tetradecapeptide toxin from wasp venom containing the structural α-amidated isoform of the Leu residue (−Leu–NH₂)] [51].

The high specificity and selectivity exhibited by P18C5 mAb in recognizing the condensed amide (−NH₃) substitutent at the carbonyl group (−CO–NH₂) of the asymmetric carbon (Ca) in the amino acid, may be due to the sort of complementarity determining regions (CDRs) encoded along both the heavy and light chains of the antibody, enhancing its preferential affinity and recognition for the structural amide (−NH₂) epitope over the functional carbonyl group (−C = O) of the amino acid [29, 30]. In same line, specific mAbs were shown to display predominant specificities and selectivity in the recognition of small antigens (≤0.3 kD) such as, acetyllysine and –methyllysine antigenic epitopes in proteins [31], or mAbs shown to discriminate among isovariants (α, β, γ, and δ) of the immune mediator, interleukin, IL-32 [30].

Based on our immunoassay results, we explored the capability of the P18C5 mAb to detect valine amide peptide immunoreactivity along the neuroaxis of the rat brain and rat neuroendocrine tissues (pituitary and adrenals) (Figs. 2 and 7). Our results showed that P18C5 mAb to was able to recognize the structural α-amidated isoform of the valine residue in endogenous peptide material, as demonstrated for abolishment of mAb immunostaining in tested tissues (Fig. 2a–c) after preadsorbing the antibody with the synthetic valine amidated residue (Val-CONH₂) (see “Materials and methods”). As shown in Fig. 2, the intermediate lobe (IL) of the pituitary (used as the internal control for the detection of immunoreactive signals in along the neuroaxis of the rat brain (Fig. 3) showed an intense mAb immunostaining when compared to absence of immunolabeling in both AL and the PL in same neuroendocrine tissue (Fig. 2a). This neurosecretory area contains the “pituitary melanotrophs” shown to synthesize and release high concentrations of POMC-derived peptides (β-endorphin, ACTH, and α-MSH) into the bloodstream [47]. Thus, the detection of P18C5 mAb-ir in the IL of the hypophysis reflects the post-translational processing of POMC-derived peptides and conversion of mature C-terminal amidated peptide products, via the activity peptidylglycine α-amidating monoxygenase (PAM) [4–6, 47]. In same line, the detection of P18C5 mAb-ir at the core (me) of the adrenal gland supports the cellular expression of bioactive methorphamide/
adrenorphin peptide released from the proenkephalin A protein precursor from the chromaffin cells [48, 52].

P18C5 mAb-immunoreactivity showed a wide distribution along the neuroaxis of the rat brain (Fig. 7a–e). Most of the rostrocaudal areas expressing a low-to moderate or conspicuous immunostaining were matched with brain areas previously shown to contain the most prevalent bioactive valine amide neuropeptides α-MSH (α-MSH) [33]; secretin (Sec) [35]; adrenorphin (Met) [34] and UCNs (UCN1-2) [36], suggesting that these peptides exert pleiotropic effects in time and tissue-specific manner, in both central and peripheral tissues after targeting their specific cell surface receptors [54, 55]. The properties and functions of valine amide peptide in the brain and peripheral tissues may be search in the web and in some reviews described herein [2, 47, 50, 53–56] and is out of the scope of the present paper to detail the relationship between brain structure and valine amide peptide bioactivities.

Data obtained from the subtraction analysis revealed the expression of mAb-immunolabeling in specific brain areas that did not match with the neuronal distribution of valine amide neuropeptides (Fig. 3). These results suggest that such areas represent neural structures able to synthesize putative novel valine amidated peptide products encoded in large propeptide precursor protein(s) with functions yet to be elucidated. Furthermore, these areas suggest that neurons operating within each immunolabeled brain region or nuclei must express same molecular machinery and posttranslational enzyme-dependent mechanisms, in order to allow the biosynthesis and conversion of prohormones into functional C-terminal amide neuropeptides [1–3, 19, 47, 49, 50] at the expense of the functional bioactivities of PC1/PC3 proconvertases [47, 57] and the peptidylglycine α-amidating monoxygenase (PAM) [4], respectively.

This hypothesis is supported by the specific tissue-dependent processing of POMC-derived peptide hormones (α-MSH, ACTH, β-endorphin) [47] in the brain and peripheral tissues [57], including the processing of proenkephalin A in the brain and neurosecretory tissues such as, the chromaffin cells of the adrenal medulla (me) [52].

Moreover, based on the specificity and selectivity of the P18C5 mAb for detecting immunoreactive peptide material in the rat brain and neuroendocrine tissues; we explored the feasibility of this mAb to determine the abundance of Val-CONH₂-ir peptide fractions isolated from immunostained subtracted regions using our fmol-sensitive solid-phase RIA raised for P18C5 mAb (Fig. 6). As shown, both cortex (Cx), brainstem (BS) and Cb were used as representative subtracted brain areas encoding putative valine amide peptide material, in addition of the pancreas, the pituitary and adrenal glands, used as neuroendocrine control tissues (Fig. 8).

Furthermore, the highest amount of Val-CONH₂-ir peptide material was detected in the pituitary (PIT) followed by the brainstem (BS), the adrenal gland (AD) and the cortex (Cx) (Fig. 8). The relative abundance of immunoreactive peptide material determined in both BS, AD and the Cx were 46.6, 15 and 17.5 %, respectively, from that detected in the pituitary. In same line, both cerebellum (Cb) and pancreas (PNCR) showed lowest content of estimated Val-CONH₂-ir (1.1–1.8 %). Differences in the relative amount of peptide immunoreactivity estimated for each neural tissue could rely on the cell concentration of valine amide neuropeptides stored (in secretory granules) before their release into the extracellular milieu [6, 58] at the time of tissue extraction and preparation of peptide fractions from tissue homogenates. Although at this stage during mAb screening, the exact amount of putative novel valine amide neuropeptides per tissue (in the case of their existence) may be impossible to obtain. However, both recombinant DNA technology and cloning procedures [27] may lead to the identification and characterization of putative novel cDNAs encoding valine amide peptide sequences, as demonstrated for the “enterins”, a family of structurally related nonapeptides and decapeptides that are present in the gut and CNS of Aplysia, and most of which share the HSFVamide sequence at the C terminus [24].

**Conclusions**

The present work describes an experimental strategy used to generate murine monoclonal antibodies able to differentiate between two isovariants of the valine residue. One single mAb designated as, P18C5 mAb, showed a unique specificity and selectivity for the structural α-amidated isoform of this neutral amino acid in natural (metorphamide/adrenorphin) and synthetic (–Val-CONH₂) peptide antigens, as revealed from our immunoassays, besides of demonstrating a great capability to detect putative—yet unidentified—valine amide peptide immunoreactive material in specific areas of the rat brain. The ability of this mAb to distinguish between two small structural epitopes in same residue, posit for its wide applications in both research and clinical settings. For instance, P18C5 mAb may be used to generate specific biological “kits” used to purify and detect valine amidated peptide products in tissue and/or biological fluids. Furthermore, this mAb may be used in immunotherapy settings to reduce tumor growth and tumorigenesis; or used as a detoxifying–neutralizing reagent from blood poisoning compounds such as, toxic amidated peptide molecules found in food, plants and/or animal species. Overall, this work portraits the potential applications of a single mAb, who displays exquisite properties when reacting against valine amide peptide antigens, including its capability to identify brain regions expressing putative novel valine amide neuropeptides, with functions yet to be discovered.
Authors' contributions
BA conceived the study. BA and PL participated in the design and coordination of the study, data analysis, and drafting of the manuscript. JAH participated in the design and synthesis of the immunocoujugates. MM and RH, together with BA, conducted all immunosays related to the generation of hyperimmune mice, cell fusion and the generation and expansion of productive hybridomas and collected data for the manuscript. JC and JAH participated in the ELISAs for monoclonal and polyclonal antibodies, as well as protein determination and the collection of data for the present manuscript. RA and AY participated in the immunohistochemistry studies. Both investigators BA and PL were involved in the collection of data. AS performed the subtraction analysis of positive immunoreactive areas for the P185 C mAb and performed the statistical analysis for this study. All authors helped to draft the manuscript, read and approved the final manuscript, and agreed on its submission. All authors read and approved the final manuscript.

Author details
1 Molecular Neurobiology and Addictive Neurochemistry Laboratory, National Institute of Psychiatry, Calzada México-Xochimilco #101, 14370 México D.F., Mexico. 2 Present Address: Department of Neuroscience, National Institute of Perinatology, Montes Urales # 800, 11000 México D.F., Mexico.

Acknowledgements
This work was kindly funded by the following grants: NIDA-NIHPAS-08-061; INFRM-IC922019; ICTDF-2007; CONACYT/SEP-CO1-47804; CONACYT/OSIS/SIG/SALUD-2007-CO1-69373; and Megaproyecto UNAM MP6-16, Fundación Gonzalo RioArronte A.C.

Compliance with ethical guidelines

Competing interests
The authors declare that they have no competing interests. We declared that no financial competing interests exist. Our institutional grant will provide the fees requested upon considering the publication of the article. We declare that we do not hold any stocks or shares in any organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. In addition, we declare that there are no current applications for any patents related to the content of the present manuscript and that no other financial competing interests regarding the content of this manuscript exist.

Received: 27 March 2015 Accepted: 1 October 2015

Published online: 13 October 2015

References
1. Elphick MR, Mirabeau O. The evolution and variety of RFamide-type neuropeptides: insights from deuterostomian invertebrates. Front Endocrinol Lausanne. 2014;5:93.
2. Baldwin GS, Patel O, Shulkes A. Evolution of gastrointestinal hormones: the cholecystokinin/gastrin family. Curr Opin Endocrinol Diabetes Obes. 2010;17:77–88.
3. Hewers RS, Taghert PH. Neuropeptides and neuropeptide receptors in the Drosophila melanogaster genome. Genome Res. 2001;11:1126–42.
4. Chufán EE, De M, Eipper BA, Mains RE, Amzel LM. Amidation of bioactive peptides: the structure of the lyase domain of the amidating enzyme. Structure. 2009;17:965–73.
5. Bousquet-Moore D, Mains RE, Eipper BA. Peptidylglycine α-amidating monoxygenase and copper: a gene-nutrient interaction critical to nervous system function. J Neurosci. 2010;30:8235–45.
6. Rajagopal C, Stone KL, Mains RE, Eipper BA. Secretion stimulates intramembrane proteolysis of a secretory granule membrane enzyme. J Biol Chem. 2010;285:34632–44.
7. Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper mono-oxygenases and peptide amidation: structure, mechanism and function. Cell Mol Life Sci. 2000;57:1236–59.
8. Eipper BA, Milgranen L, Husten EJ, Yun HY, Mains RE. Peptidylglycine alpha-amidating monoxygenase: a multifunctional protein with catalytic, processing, and routing domains. Protein Sci. 1993;2:489–97.
9. Kolhekar AS, Bell J, Shiozaki EN, Jin L, Keutmann HT, Hand TA, Mains RE, Eipper BA. Essential features of the catalytic core of peptidyl-alpha-hydroxylating alpha-amidating lyase. Biochemistry. 2002;41:12386–94.
10. Merkler DJ, Kalathila R, Consolvo AP, Young SD. Ash DE:180 isoform 13C NMR shift as proof that bifunctional peptidylglycine alpha-amidating enzyme is a monoxygenase. Biochemistry. 1992;31(32):7282–8.
11. Chen P, Solomon E. Oxygen activation by the noncooperative binuclear copper site in peptidylglycine alpha-hydroxylating monoxygenase. Reaction mechanism and role of the noncooperative nature of the active site. J Am Chem Soc. 2004;126:4991–5000.
12. Cyzyk TA, Ning Y, Hsu MS, Peng B, Mains RE, Eipper BA, Pintar JE. Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse. Dev Biol. 2005;287:301–13.
13. Lénard L, Kovác A, Olímann T, Péczely L, Zagorac O, Gálosi R, László K. Positive reinforcing effects of RFamide-related peptide-1 in the rat central nucleus of amygdala. Behav Brain Res. 2014;275:101–6.
14. Sharma SD, Rachguraman G, Lee MS, Prabhakar NR, Kumar GK. Intermittent hypoxia activates peptidylglycine alpha-amidating monoxygenase in rat brain stem via reactive oxygen species-mediated proteolytic processing. J Appl Physiol. 2009;106:12–9.
15. Merkler DJ. C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzym Microb Technol. 1994;16:450–6.
16. Tsutsui K, Ukena K. Hypothalamic LPXRF-amide peptides in vertebrates: identification, localization and hypophysiotropic activity. Peptides. 2006;25:1121–9.
17. Seizinger RR, Liebisch DC, Gramsch C, Herz A, Weber E, Evans CJ, Esch FS, Böhlen P. Isolation and structure of a novel C-terminally amidated opioid peptide, amidorphin, from bovine adrenal medulla. Nature. 1985;313:57–9.
18. Jensen TD, Holst JJ, Fahrenkrug J. Secretion of pancreaticpolptides from the porcine digestive tract. Scand J Gastroenterol. 1994;29:376–84.
19. Lovejoy DA, Balment RJ. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. Gen Comp Endocrinol. 1999;115:1–22.
20. Vinson GP, Whitehouse BJ, Dell A, Etienne T, Morris HR. Characterisation of an adrenal zona glomerulosa-stimulating component of posterior pituitary extracts as alpha-MSH. Nature. 1980;284(5755):464–7.
21. Weber E, Esch FS, Böhlen P, Paterson S, Corbrett AD, McKnight AT, Kosterlitz HW, Barchas JD, Evans CJ. Metorphamide: isolation, structure, and biologic activity of an amidated opioid octapeptide from bovine brain. Proc Natl Acad Sci USA. 1983;80:7362–6.
22. Nilsson A, Carlquist M, Jörnvall H, Mutt V. Isolation and characterization of chicken secretin. Eur J Biochem. 1980;112:383–8.
23. Lederis K, Letter A, Mcmaster D, Moore G, Schlesinger D. Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing peptide from the catfish. Proc Natl Acad Sci USA. 1983;80:6404–8.
24. Lederis K, Letter A, Mcmaster D, Moore G, Schlesinger D. Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing peptide from the catfish. Proc Natl Acad Sci USA. 1983;80:6404–8.
25. Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper mono-oxygenases and peptide amidation: structure, mechanism and function. Cell Mol Life Sci. 2000;57:1236–59.
26. Grant GA, Crankshaw MW, Gorka J. Edman sequencing as tool for characterisation of synthetic peptides. Methods Enzymol. 1997;289:395–419.
27. Glick RB, Pasternak JJ. Recombinant DNA technology. In: Glick RB, Pasternak JJ, editors. Molecular biotechnology: principles and applications of recombinant DNA. Washington: ASM Press; 1998. p. 45–77.
28. Zhu P, Bowden P, Zhang D, Marshall JG. Mass spectrometry of peptides and proteins from human blood. Mass Spectrom Rev. 2011;30(5):685–732.
29. Godding JW. Monoclonal antibodies: principles and practice. In: Goding JW, editor. Production and application of monoclonal antibodies in cell biology, biochemistry and immunology. 3rd ed. London: Academic Press; 1996. p. 141–180.
30. Kim KH, Sim JJ, Seo EH, Cho MC, Kang JW, Kim SH, YU DY, Song EY, Lee HG, Sohn JH, Kim J, Dinarello CA, Yoon DY. Interleukin-12 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA. J Immunol Methods. 2008;333:38–50.
31. Iwabata H, Yoshida M, Komatsu Y. Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylolation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics. 2005;5(18):4653–64.

32. Jacobowitz DM, O’Donohue TL. Alpha-melanocyte stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain. Proc Natl Acad Sci USA. 1978;75:6300–4.

33. Oliver C, Porter JC. Distribution and characterization of alpha-melanocyte-stimulating hormone in the rat brain. Endocrinology. 1978;102:697–705.

34. Sanders M, Brachas JD, Weber E. Regional distribution of metorphamide in rat and guinea pig brain. Biochem Biophys Res Commun. 1984;122:892–8.

35. O’Donohue TL, Charlton CG, Miller RL, Boden G, Jacobowitz DM. Identification, characterization, and distribution of secretin immunoactivity in rat and pig brain. Proc Natl Acad Sci USA. 1981;78:5221–4.

36. Kozicz T, Tama halfa H, Anmura A. Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J Comp Neurol. 1998;391:1–10.

37. Solcia E, Usellini L, Buffa R, Rindi G, Villani L, Zampatti C, Silini E. Endocrine cells producing regulatory peptides. Experientia. 1987;43:389–50.

38. Luger TA, Scholzen TE, Brozoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133–40.

39. Harlow E, Lane D. Using antibodies: a laboratory manual. In: Harlow ED, Lane D editors. New York: Cold Spring Harbor Laboratory Press; 1996. p. 222–66.

40. Ohnishi S, Kamikubo H, Onitsuka M, Kataoka M, Shortle D. Conformational preference of polyglycine in solution to elongated structure. J Am Chem Soc. 2006;128:16338–44.

41. Hockfeld S, Carlson S, Evans C, Levitt P, Pintar J, Silberstein L. Selected methods for antibody and nucleic acid probes. In: Hockfeld S, Carlson S, Evans C, Levitt P, Pintar J, Silberstein L. editors. Molecular probes of the nervous system. New York: Cold Spring Harbor Laboratory Press; 1993. p. 263–302.

42. de St Groth SF, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods. 1980;35:1–21.

43. Lai PK, McGraw HF, Tublitz NJ. Peptide detection in single cells using a dot immunoblot assay. Peptides. 1997;18:749–53.

44. Asai M, Zubieta M, Matamoros-Trejo G, Linares G, Agustin P. Diurnal variations of opioid peptides and synenkephalin in vitro release in the amygdala of kindled rats. Neuropeptides. 1998;32:293–9.

45. Anton B, Fein J, To T, Li X, Silberstein L, Evans C. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol. 1996;368:229–51.

46. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. New York: New York Academic Press; 1998.

47. Bicknell AB. The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol. 2008;20:692–9.

48. Boarder MR, Contractor H, Marriott D, Mcdardle W. Metorphamide, a C-terminally amidated opioid peptide, in human adrenal and human phaeochromocytoma. Regul Pept. 1985;12:35–42.

49. Fekete EM, Zorrilla EP. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol. 2007;28:1–27.

50. Shioda S, Ohtaki H, Nakamachi T, Dohi K, Watanabe J, Nakajo S, Arata S, Kitamura S, Okuda H, Takeno Y, Kitamura Y. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann N Y Acad Sci. 2006;1070:550–60.

51. Higashijima T, Izu S, Nakajima T, Ross EM. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem. 1988;263(14):6491–4.

52. Tezapsidis N, Parish DC. Characterization of a metalloprotease from ovine chromaffin granules, which deaves a proenkephalin fragment (BAM12P) at a single arginine residue. Biochem J. 1994;301:607–14.

53. Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci. 2008;31:333–40.

54. Brozoska T, Böhm M, Luger TA, Luger K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107–16.

55. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fourrier A, Chow BK, Hashimoto H, Galas L, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61:283–357.

56. Rehfeld JF, Bundgaard JR, Goetze JP, Friis-Hansen L, Hilsted L, Johnsen AH. Naming progastrin-derived peptides. Regul Pept. 2004;120:177–83.

57. D’Agostino G, Diano S. Alpha-melanocyte stimulating hormone: production and degradation. J Mol Med Berlin. 2010;88(12):1195–201.

58. Loh YP, Kim T, Rodriguez YM, Cawley NX. Secretory granule biogenesis and neuropeptide sorting to the regulated secretory pathway in neuroendocrine cells. J Mol Neurosci. 2004;22:63–71.